{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,5]],"date-time":"2026-01-05T21:46:28Z","timestamp":1767649588361},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"6","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2013,6]]},"DOI":"10.1007\/s12325-013-0038-z","type":"journal-article","created":{"date-parts":[[2013,6,25]],"date-time":"2013-06-25T12:03:55Z","timestamp":1372161835000},"page":"630-643","source":"Crossref","is-referenced-by-count":9,"title":["Moxifloxacin in Complicated Skin and Skin Structure Infections (cSSSIs): A Prospective, International, Non-Interventional, Observational Study"],"prefix":"10.1007","volume":"30","author":[{"given":"Johannes R.","family":"Bogner","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ammar","family":"Kutaiman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melanie","family":"Esguerra-Alcalen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Heldner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pierre","family":"Arvis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,6,25]]},"reference":[{"key":"38_CR1","doi-asserted-by":"crossref","unstructured":"Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65:iii35\u201344.","DOI":"10.1093\/jac\/dkq302"},{"key":"38_CR2","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1086\/367653","volume":"36","author":"JJ Engemann","year":"2003","unstructured":"Engemann JJ, Carmeli Y, Cosgrove SE, et al. Adverse clinical and economic outcomes attributable to methicillin resistance among patients with Staphylococcus aureus surgical site infection. Clin Infect Dis. 2003;36:592\u20138.","journal-title":"Clin Infect Dis"},{"key":"38_CR3","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1111\/j.1742-4801.2004.00067.x","volume":"1","author":"DJ Leaper","year":"2004","unstructured":"Leaper DJ, van Goor H, Reilly J, et al. Surgical site infection\u2014a European perspective of incidence and economic burden. Int Wound J. 2004;1:247\u201373.","journal-title":"Int Wound J."},{"key":"38_CR4","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1086\/520743","volume":"28","author":"BA Lipsky","year":"2007","unstructured":"Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin and soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical and economic outcomes. Infect Con Hosp Epidemiol. 2007;28:1290\u20138.","journal-title":"Infect Con Hosp Epidemiol."},{"key":"38_CR5","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1469-0691.2008.02123.x","volume":"14","author":"M Cainzos","year":"2008","unstructured":"Cainzos M. Review of the guidelines for complicated skin and soft tissue infections and intra-abdominal infections\u2014are they applicable today? Clin Microbiol Infect. 2008;14:9\u201318.","journal-title":"Clin Microbiol Infect"},{"key":"38_CR6","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.idc.2009.04.006","volume":"23","author":"LM Napolitano","year":"2009","unstructured":"Napolitano LM. Severe soft tissue infections. Infect Dis Clin N Am. 2009;23:571\u201391.","journal-title":"Infect Dis Clin N Am."},{"key":"38_CR7","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.diagmicrobio.2006.05.009","volume":"57","author":"GJ Moet","year":"2007","unstructured":"Moet GJ, Jones RN, Biedenbacj DJ, Stilwell MG, Fritsche TR. Contemporary causes of skin and soft tissue infections in North America, Latin America, and Europe: Report from the SENTRY Antimicrobial Surveillance Program (1998\u20132004). Diag Microbiol Infect Dis. 2007;57:7\u201313.","journal-title":"Diag Microbiol Infect Dis."},{"key":"38_CR8","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1093\/jac\/dkg009","volume":"50","author":"I Brook","year":"2002","unstructured":"Brook I. Microbiology of polymicrobial abscesses and implications for therapy. J Antimicrob Chemother. 2002;50:805\u201310.","journal-title":"J Antimicrob Chemother"},{"key":"38_CR9","doi-asserted-by":"crossref","first-page":"i3","DOI":"10.1093\/jac\/dkg466","volume":"52","author":"LJ Eron","year":"2003","unstructured":"Eron LJ, Lipsky BA, Low DE, Nathwani D, Tice AD, Volturo GA. Managing skin and soft tissue infections: expert panel recommendations on key decision points. J Antimicrob Chemother. 2003;52:i3\u201317.","journal-title":"J Antimicrob Chemother"},{"key":"38_CR10","doi-asserted-by":"crossref","first-page":"1373","DOI":"10.1086\/497143","volume":"41","author":"DL Stevens","year":"2005","unstructured":"Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41:1373\u2013406.","journal-title":"Clin Infect Dis"},{"key":"38_CR11","doi-asserted-by":"crossref","unstructured":"May AK, Stafford RE, Bulger EM, et al. Surgical Infection Society Guidelines. Treatment of complicated skin and soft tissue infections. Surg Infect. 2009;10:467\u201399.","DOI":"10.1089\/sur.2009.012"},{"key":"38_CR12","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1093\/cid\/ciq146","volume":"52","author":"C Liu","year":"2011","unstructured":"Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the Infectious Diseases Society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52:e18\u201355.","journal-title":"Clin Infect Dis"},{"key":"38_CR13","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1002\/dmrr.2251","volume":"28","author":"BA Lipsky","year":"2012","unstructured":"Lipsky BA, Peters EJ, Berendt AR, et al. Specific guidelines for the treatment of diabetic foot infections 2011. Diabetes Metab Res Rev. 2012;28:234\u20135.","journal-title":"Diabetes Metab Res Rev."},{"key":"38_CR14","doi-asserted-by":"crossref","first-page":"309","DOI":"10.2147\/tcrm.2007.3.2.309","volume":"3","author":"P Giordano","year":"2007","unstructured":"Giordano P, Weber K, Gesin G, Kubert J. Skin and skin structure infections: treatment with newer generation fluoroquinolones. Ther Clin Risk Manag. 2007;3:309\u201317.","journal-title":"Ther Clin Risk Manag"},{"key":"38_CR15","doi-asserted-by":"crossref","first-page":"4117","DOI":"10.2147\/tcrm.2006.2.4.417","volume":"2","author":"D Guay","year":"2006","unstructured":"Guay D. Moxifloxacin in the treatment of skin and skin structure infections. Ther Clin Risk Manag. 2006;2:4117\u201334.","journal-title":"Ther Clin Risk Manag"},{"key":"38_CR16","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s15010-009-8468-x","volume":"37","author":"R Vick-Fragoso","year":"2009","unstructured":"Vick-Fragoso R, Hern\u00e1ndez-Oliva G, Cruz-Alc\u00e1zar J, STIC Study Group, et al. Efficacy and safety of sequential intravenous\/oral moxifloxacin vs intravenous\/oral amoxicillin\/clavulanate for complicated skin and skin structure infections. Infection. 2009;37:407\u201317.","journal-title":"Infection"},{"key":"38_CR17","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.ijantimicag.2005.07.017","volume":"26","author":"P Giordano","year":"2005","unstructured":"Giordano P, Song J, Pertel P, Herrington J, Kowalsky S. Sequential intravenous\/oral moxifloxacin versus intravenous piperacillin-tazobactam followed by oral amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections. Int J Antimicrob Agents. 2005;26:357\u201365.","journal-title":"Int J Antimicrob Agents"},{"key":"38_CR18","doi-asserted-by":"crossref","first-page":"2632","DOI":"10.1093\/jac\/dkr344","volume":"66","author":"IC Gyssens","year":"2011","unstructured":"Gyssens IC, Dryden M, Kujath P, et al. A randomised trial of the efficacy and safety of sequential IV\/oral moxifloxacin monotherapy versus IV piperacillin\/tazobactam followed by oral amoxicillin\/clavulanate for complicated skin and skin structure infections. J Antimicrob Chemother. 2011;66:2632\u201342.","journal-title":"J Antimicrob Chemother"},{"key":"38_CR19","unstructured":"European Medicines Agency. Guideline on the evaluation of medicinal products indicated for treatment of bacterial infections. Available at: www.ema.europa.eu\/docs\/en_GB\/document_library\/Scientific_guideline\/2009\/09\/WC500003417.pdf . Last accessed 30 May 2013."},{"key":"38_CR20","unstructured":"Avelox (moxifloxacin 400\u00a0mg\/250\u00a0ml solution for infusion) (product information). Leverkusen, Germany: Bayer Pharma AG; 2011."},{"key":"38_CR21","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1136\/hrt.2003.017269","volume":"90","author":"P Jepsen","year":"2004","unstructured":"Jepsen P, Johnsen SP, Gillman MW, S\u00f8rensen HT. Interpretation of observational studies. Heart. 2004;90:956\u201360.","journal-title":"Heart"},{"key":"38_CR22","first-page":"57","volume":"1","author":"V Suvarna","year":"2010","unstructured":"Suvarna V. Phase IV of drug development. Perspect Clin Res. 2010;1:57\u201360.","journal-title":"Perspect Clin Res."},{"key":"38_CR23","unstructured":"US Department of Health and Human Services, Food and Drug Administration. Guidance for industry. Acute bacterial skin and skin structure infections: developing drugs for treatment. Available at: www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM071185.pdf . Last accessed 30 May 2013."},{"key":"38_CR24","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s15010-012-0367-x","volume":"41","author":"NC Schaper","year":"2013","unstructured":"Schaper NC, Dryden M, Kujath P, et al. Efficacy and safety of IV\/PO moxifloxacin and IV piperacillin\/tazobactam followed by PO amoxicillin\/clavulanic acid in the treatment of diabetic foot infections: results of the RELIEF study. Infection. 2013;41:175\u201386.","journal-title":"Infection"},{"key":"38_CR25","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1086\/656431","volume":"51","author":"TC Jenkins","year":"2010","unstructured":"Jenkins TC, Sabel AL, Sarcone EE, Price CS, Mehler PS, Burman WJ. Skin and soft-tissue infections requiring hospitalization at an academic medical center: opportunities for antimicrobial stewardship. Clin Infect Dis. 2010;51:895\u2013903.","journal-title":"Clin Infect Dis"},{"key":"38_CR26","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/11634300-000000000-00000","volume":"12","author":"PM Tulkens","year":"2012","unstructured":"Tulkens PM, Arvis P, Kruesmann F. Moxifloxacin safety: an analysis of 14\u00a0years of clinical data. Drugs R D. 2012;12:71\u2013100.","journal-title":"Drugs R D."},{"key":"38_CR27","doi-asserted-by":"crossref","unstructured":"Moran GJ, Abrahamian FM, Lovecchio F, Talan DA. Acute bacterial skin infections: developments since the 2005 Infectious Diseases Society of America (IDSA) guidelines. J Emerg Med. 2013;44:e397\u2013412.","DOI":"10.1016\/j.jemermed.2012.11.050"},{"key":"38_CR28","first-page":"64","volume":"17","author":"E Concia","year":"2009","unstructured":"Concia E. Therapy of SSTI and role of tigecycline. Infez Med. 2009;17:64\u201376.","journal-title":"Infez Med."}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-013-0038-z","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,21]],"date-time":"2017-06-21T11:13:11Z","timestamp":1498043591000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12325-013-0038-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,6]]},"references-count":28,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2013,6]]}},"alternative-id":["38"],"URL":"https:\/\/doi.org\/10.1007\/s12325-013-0038-z","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,6]]}}}